Characteristics | POLE (n = 4) | MSI-M (n = 29) | MSI-U (n = 36) | non-MSI (n = 944) | P value | |
---|---|---|---|---|---|---|
Age | Mean (range) | 52.5 (41–63) | 76.9 (60–89) | 59.5 (24–87) | 66.0 (21–95) |  < .0001 |
 |  > 70 | 0 (0) | 22 (75.9) | 7 (19.4) | 365 (38.7) |  < .0001 |
 | 55–69 | 2 (50%) | 7 (24.1) | 18 (50.0) | 441 (46.7) |  |
 | 40–54 | 2 (50%) | 0 (0) | 7 (19.4) | 118 (12.5) |  |
 |  < 39 | 0 (0) | 0 (0) | 4 (11.1) | 20 (2.1) |  |
Gender | Female | 2 (50%) | 19 (65.5%) | 13 (36.1%) | 389 (41.2%) | 0.0593 |
 | Male | 2 (50%) | 10 (34.5%) | 23 (63.9%) | 555 (58.8%) |  |
Tumour location | Right | 4 (100%) | 27 (93.1%) | 13 (36.1%) | 282 (29.9%) |  < .0001 |
 | Left | 0 (0) | 2 (6.9%) | 23 (63.9%) | 662 (70.1%) |  |
Histology | Well | 0 (0) | 7 (24.1%) | 6 (16.7%) | 276 (29.2%) |  < .0001 |
 | Moderate | 3 (75%) | 7 (24.1%) | 20 (55.6%) | 571 (60.5%) |  |
 | Poor/muc | 1 (25%) | 15 (51.7%) | 10 (27.8%) | 97 (10.3%) |  |
UICC stage | I | 1 (25%) | 11 (37.9%) | 14 (38.9%) | 197 (20.9%) | 0.0011 |
 | II | 3 (75%) | 10 (34.5%) | 14 (38.9%) | 246 (26.1%) |  < .0001* |
 | III | 0 (0) | 6 (20.7%) | 4 (11.1%) | 297 (31.5%) |  |
 | IV | 0 (0) | 2 (6.9%) | 4 (11.1%) | 204 (21.6%) |  |
RAS mutational status | BRAF mutation | 0 (0) | 20 (69.0%) | 4 (11.1%) | 35 (3.7%) |  < .0001 |
 | KRAS mutation | 0 (0) | 0 (0) | 8 (22.2%) | 307 (32.5%) |  |
 | Wild-type | 4 (100%) | 9 (31.0%) | 24 (66.7%) | 602 (63.8%) |  |
Methylation score | Mean (range) | 2 (2) | 3.2 (2–4) | 1.9 (0–4) | 1.9 (0–4) |  < .0001 |
MGMT methylation | Extensive | 0 (0) | 17 (58.6%) | 4 (11.1%) | 166 (17.6%) |  < .0001 |
 | Partial | 0 (0) | 1 (3.5%) | 5 (13.9%) | 60 (6.4%) |  |
 | Unmethylation | 4 (100%) | 11 (37.9%) | 27 (75.0%) | 718 (76.1%) |  |
SFRP2 methylation | Extensive | 4 (100%) | 28 (96.6%) | 23 (63.9%) | 602 (63.8%) | 0.0158 |
 | Partial | 0 (0) | 1 (3.5%) | 8 (22.2%) | 194 (20.6%) |  |
 | Unmethylation | 0 (0) | 0 (0) | 5 (13.9%) | 148 (15.7%) |  |